贝塞特病中的肺高血压:心声学查和多学科方法
Berkan Armağan1, Metin Okşul2, Yusuf Ziya Şener2
1Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Turkish journal of medical sciences
|July 21, 2023
概括
肺高血压 (PH) 影响11%的贝塞特病 (BD) 患者,通常与心脏或肺部问题有关. 血管参与BD增加PH风险,需要对这些患者的PH进行监测.
科学领域:
- 类风湿病学 类风湿病学
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
背景情况:
- 肺高血压 (PH) 在贝赫塞特病 (BD) 中是鲜为人知的.
- 在BD中PH的患病率和原因需要进一步调查.
研究的目的:
- 为了确定BD患者PH的患病率.
- 为了确定BD中PH的原因.
主要方法:
- 154名BD患者通过心声扫描 (sPAP ≥40 mmHg) 进行PH查.
- 患者按器官参与 (粘膜皮肤/关节,眼睛,血管,肠道,神经系统) 进行分类.
- 使用实验室和成像数据调查PH的原因.
主要成果:
- 在11% (17/154) 的BD患者中检测到PH.
- 主要的PH类型是II组 (心脏左侧疾病) 和IV组 (肺动脉干扰).
- 在患有血管干扰的BD患者中观察到更高的PH频率 (52.9%对28.5%,p=0.04).
结论:
- 在BD患者中,PH并不罕见.
- 左心脏病和肺动脉干扰是BD中PH的常见原因.
- 血管参与BD是PH的危险因素;建议监测BD患者的肺动脉参与IV组PH.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
228
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
228
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
209
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
209
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
38
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
Cardiomyopathy V: Interprofessional Care
17
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
17


